Search

MediciNova Inc

Fechado

SetorSaúde

1.54 1.32

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.45

Máximo

1.56

Indicadores-chave

By Trading Economics

Rendimento

-4.9B

-4.9B

Vendas

271K

458K

EPS

-0.05

Margem de lucro

-1,068,366.946

Funcionários

6

EBITDA

5.1K

-2.5M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+422.88% upside

Dividendos

By Acuity

Próximos Ganhos

10 de nov. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

65M

Abertura anterior

0.22

Fecho anterior

1.54

Sentimento de Notícias

By Acuity

50%

50%

150 / 340 Ranking em Healthcare

MediciNova Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

24 de ago. de 2026, 20:02 UTC

MediciNova Inc shares are higher today, continuing a strong upward trend since Friday's close. The stock remains near the upper end of its one-month range.

21 de ago. de 2026, 19:56 UTC

MediciNova Inc's shares are higher today, continuing a positive trend. The stock is trading above its 20-day moving average amid gains in the cryptocurrency sector.

20 de ago. de 2026, 19:16 UTC

MediciNova Inc. shares are lower today, having previously declined significantly before recovering. The price remains above its 20-day moving average.

18 de ago. de 2026, 19:56 UTC

MediciNova Inc shares are higher, reflecting positive market momentum. The stock remains above its 20-day moving average and near the upper end of its one-month range.

17 de ago. de 2026, 19:56 UTC

News

MediciNova shares are higher as the company reported earnings of -$0.05 per share, surpassing estimates and generating $0.46 million in revenue.

13 de ago. de 2026, 19:26 UTC

MediciNova Inc shares are lower amid broader market pressure from rising jobless claims and stabilizing inflation indicators. The stock trades near its one-month range low.

12 de ago. de 2026, 19:56 UTC

MediciNova Inc. shares are trading roughly flat with no specific news identified, remaining near the lower end of their one-month trading range.

11 de ago. de 2026, 20:06 UTC

MediciNova Inc. shares are roughly flat, showing little movement since Monday's close and positioned near the lower end of their one-month trading range.

10 de ago. de 2026, 19:46 UTC

MediciNova Inc shares are lower today, continuing a downward trend since Friday. Broader market sentiment is affected by recent U.S. employment data.

7 de ago. de 2026, 19:46 UTC

MediciNova Inc. shares are higher today, recovering from earlier losses. The stock is trading around the middle of its one-month range.

6 de ago. de 2026, 20:13 UTC

MediciNova Inc shares are higher in after-market trading, reflecting strength since Thursday's close amid rising U.S. Treasury yields and a hawkish Fed outlook.

4 de ago. de 2026, 19:36 UTC

MediciNova Inc. shares are trading roughly flat amid broader market reactions to a decline in U.S. core factory orders and ongoing strength in AI sectors.

3 de ago. de 2026, 20:06 UTC

MediciNova Inc. shares are lower, continuing a decline since Friday's close, despite positive movements in major indices like the S&P 500 and Nasdaq 100.

31 de jul. de 2026, 19:56 UTC

Shares of MediciNova Inc. are lower during Friday's session, following a routine decline after an early high. The stock is below its 20-day moving average.

30 de jul. de 2026, 20:51 UTC

MediciNova Inc's shares are lower in after-market hours, reflecting a broader decline in the Biotechnology sub-sector. The asset is near its one-month trading range low.

29 de jul. de 2026, 20:09 UTC

MediciNova Inc shares are lower today, continuing a decline since Tuesday's close, and remain near their opening low amid broader market trends.

28 de jul. de 2026, 18:46 UTC

MediciNova Inc. shares are trading higher today, remaining above Monday's close despite settling back from earlier gains during the session.

27 de jul. de 2026, 19:06 UTC

MediciNova Inc. shares are lower today, reflecting broader market trends amid a significant decline in crude oil prices following eased geopolitical tensions.

24 de jul. de 2026, 23:02 UTC

MediciNova Inc shares increased in after-hours trading, reflecting strong performance since Friday's close, despite mixed market sentiment and no specific company news.

23 de jul. de 2026, 20:06 UTC

MediciNova Inc. shares are lower today, continuing a six-session decline amid routine volatility and remaining significantly below the 20-day moving average.

21 de jul. de 2026, 19:21 UTC

MediciNova Inc. shares are lower amid no specific news, continuing a trend below the 20-day moving average over the past three sessions.

Comparação entre Pares

Variação de preço

MediciNova Inc Previsão

Preço-alvo

By TipRanks

422.88% parte superior

Previsão para 12 meses

Média 8 USD  422.88%

Máximo 10 USD

Mínimo 6 USD

Com base em 2 analistas de Wall Street que oferecem metas de preço de 12 meses para MediciNova Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

2 ratings

2

Comprar

0

Manter

0

Vender

Sentimento

By Acuity

150 / 340 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre MediciNova Inc

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.
help-icon Live chat